Mus­tang ties the knot with Fred Hutch on next-gen CAR-T for lym­phoma

Back in ear­ly Feb­ru­ary, Mus­tang Bio — a sub of Fortress Biotech $FBIO — said it had raised a whop­ping $94.5 mil­lion to bol­ster its work on new CAR-T ther­a­pies. And this morn­ing it’s fol­lowed through with a li­cens­ing pact forged with the pres­ti­gious Fred Hutch, where it will now push a new Phase I/II clin­i­cal study in B-cell non-Hodgkin lym­phomas.

This new pro­gram comes out of the labs of Oliv­er Press and Bri­an Till at the Hutch. They’ve been work­ing on a CAR-T that can ex­press a CD20-spe­cif­ic chimeric anti­gen re­cep­tor.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.